VF
ZVSA

Virtu Financial’s ZyVersa Therapeutics ZVSA Stock Holding History

Virtu Financial’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,527
Closed -$11K – 2106
2025
Q1 		$11K Sell
17,527
-7,732
-31% -$8.72K ﹤0.01% 1174
2024
Q4 		$27K Buy
+25,259
New +$39.9K ﹤0.01% 1253
2023
Q3 		– Sell
-344
Closed -$30K – 1994
2023
Q2 		$30K Buy
+344
New +$90.3K ﹤0.01% 1204

Other funds holding ZVSA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Virtu Financial's ZVSA Position: Q2 2025 in Review

Virtu Financial sold out of ZyVersa Therapeutics (ZVSA) in Q2 2025, closing a stake of 17,527 shares — an estimated $11K sold.

Virtu Financial first reported a position in ZVSA in Q2 2023 and held it in 3 quarters. The position peaked at $30K in Q2 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q2 2025.

  • Virtu Financial reported no remaining ZyVersa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 17,527 ZyVersa Therapeutics shares in Q2 2025, an estimated $11K.
  • Virtu Financial first reported a position in ZyVersa Therapeutics in Q2 2023 and held it in 3 quarters.
  • Virtu Financial's ZyVersa Therapeutics position peaked at $30K in Q2 2023.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.